Shield Therapeutics (LON:STX) Given "Buy" Rating at Peel Hunt

Key Points

• Peel Hunt has reissued a "buy" rating for Shield Therapeutics, setting a price objective of GBX 15, indicating a potential upside of 82.93% from its previous close.
• Shield Therapeutics' stock opened at GBX 8.20, with a market cap of £85.42 million and a current ratio of 1.05.
• The company specializes in delivering Accrufer®/Feraccru®, aimed at addressing iron deficiency in patients, having launched the product in the U.S.

Shield Therapeutics (LON:STX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Peel Hunt in a research note issued on Monday, Marketbeat.com reports. They currently have a GBX 15 price objective on the stock. Peel Hunt's price target would indicate a potential upside of 87.50% from the company's current price.

Shield Therapeutics Trading Up 0.6%

STX traded up GBX 0.05 on Monday, reaching GBX 8. 2,570,002 shares of the company's stock were exchanged, compared to its average volume of 2,770,466. The company has a market cap of £83.34 million, a price-to-earnings ratio of -400.00 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. Shield Therapeutics has a twelve month low of GBX 2.10 and a twelve month high of GBX 9.10. The company's 50 day moving average is GBX 5.92 and its 200-day moving average is GBX 3.80.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.